Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1NETWORK 1

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

CNS 2

Conditions

Medulloblastoma 2Ependymoma 1

Interventions

pembrolizumab 1254Specimen Handling 869Carboplatin 818Magnetic Resonance Spectroscopy 804Cyclophosphamide 795Cisplatin 716Nivolumab 648Paclitaxel 623Radiotherapy 567Gemcitabine 565Biopsy 529Bevacizumab 468Dexamethasone 434fludarabine 404Docetaxel 373venetoclax 366Oxaliplatin 362Capecitabine 353Fluorouracil 352atezolizumab 341Rituximab 327durvalumab 326Doxorubicin 313Radiosurgery 306Pemetrexed 303Drug Therapy 295Standard of Care 292Ipilimumab 290Etoposide 280Radiation 278

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Triiodothyronine × 1 year × Clear all
NCT07346157 2026-06-01

PNOC044

University of California, San Francisco

Phase 1/2 Not yet recruiting
69 enrolled
CNS

Medulloblastoma

NCT04743661 2026-02-05

131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma

Pediatric Brain Tumor Consortium

Phase 2 Active not recruiting
62 enrolled
CNS

Ependymoma, Medulloblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡